Boston Scientific Will Lean On Quadripolar, S-ICD To Revive Sagging U.S. CRM Sales
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific reported disappointing first-quarter results for its cardiac rhythm management division, mostly due to price erosion in the U.S and the lack of a quadripolar CRT-D device. But the firm argues that the new S-ICD and forthcoming quadripolar CRT-D products may help turn the business around soon.